{"id":"apg-1252","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"APG-1252 selectively binds to Bcl-2 and Bcl-xL proteins, disrupting their anti-apoptotic function and leading to the activation of caspases and subsequent cell death in tumor cells.","oneSentence":"APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:34:50.851Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT05691504","phase":"PHASE1","title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-14","conditions":"Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma","enrollment":42},{"nctId":"NCT04001777","phase":"PHASE1","title":"A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-07-04","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT04893759","phase":"PHASE1","title":"A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2022-01-06","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT05186012","phase":"PHASE1, PHASE2","title":"APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2022-06-14","conditions":"NHL, Adult","enrollment":51},{"nctId":"NCT03080311","phase":"PHASE1","title":"A Study of APG-1252 in Patients With SCLC or Other Solid Tumors","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2017-02-12","conditions":"Small Cell Lung Cancer, Solid Tumor","enrollment":50},{"nctId":"NCT04354727","phase":"PHASE1, PHASE2","title":"A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy","status":"WITHDRAWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-12-15","conditions":"Myelofibrosis","enrollment":""},{"nctId":"NCT04210037","phase":"PHASE1, PHASE2","title":"Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-08-20","conditions":"Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT03387332","phase":"PHASE1","title":"APG-1252 in Patients With SCLC or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2017-12-01","conditions":"Small Cell Lung Cancer and Other Solid Tumors","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["APG-1252 for injection","Pelcitoclax"],"phase":"phase_1","status":"active","brandName":"APG-1252","genericName":"APG-1252","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells. Used for Solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}